No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE-D trial

What Was Tested

The paper reports a study of Glucagon, published as a randomized controlled trial.

To assess the effects of dapagliflozin, metformin and exercise treatment on changes in plasma glucagon concentrations in individuals with overweight and HbA1c-defined prediabetes.

Linear mixed effects models with participant-specific random intercepts were used to investigate associations of the interventions with fasting plasma glucagon concentration, insulin/glucagon ratio and glucagon suppression during the OGTT.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized and double-blind study.

The participants were allocated by chance, so the Glucagon group and the comparison group should start out alike.

As a double-blind Glucagon study, the assignments were hidden from both participants and investigators until the end.

A 75-g oral glucose tolerance test (OGTT) (0, 30, 60 and 120 minutes) was administered at baseline, at 13 weeks (end of intervention) and at 26 weeks (end of follow-up).

What Was Measured

Topics PubMed links to this paper include Benzhydryl Compounds, Blood Glucose, Diabetes Mellitus, Type 2, Glucagon, Glucosides, Hypoglycemic Agents and Metformin.

Author keywords: exercise, glucagon, metformin, obesity, prediabetes, sodium-glucose co-transporter-2 inhibitor.

What This Means in Plain Language

The paper is a randomized and double-blind study of Glucagon.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2021 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Glucagon compound page, all human trials.